Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond. - Allahwala MA; Marathe CS; Nelson AJ; Psaltis PJ; Marathe JA (Heart, lung & circulation, 2025)